The relatively recent discovery of neurotrophic tropomyosin receptor kinase (NTRK) gene arrangements as pan-tumor predictive biomarkers has led to impressive novel treatments for patients with TRK fusions. Although the number of patients who qualify for treatment is vanishingly small for cancer patients in general, a few histological subsets of sarcomas exhibit NTRK fusions more commonly leading to large expectations within the sarcoma community.

中文翻译：

---

肉瘤中的原肌球蛋白受体激酶 - 喜悦和绝望。

最近发现神经营养性原肌球蛋白受体激酶 (NTRK) 基因排列作为泛肿瘤预测生物标志物，为 TRK 融合患者带来了令人印象深刻的新型治疗方法。尽管对于一般癌症患者来说，有资格接受治疗的患者数量微乎其微，但肉瘤的一些组织学亚型更常见地表现出 NTRK 融合，从而在肉瘤界引起了很大的期望。